Mercer Global Advisors
RNAC icon

Mercer Global Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Mercer Global Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.3K Buy
+7,323
New +$54.3K ﹤0.01% 4044

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Mercer Global Advisors's RNAC Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 7,323 shares worth $76.3K. The stake represents ﹤0.01% of the portfolio and ranks #4044 among its holdings.

88 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Mercer Global Advisors held 7,323 shares of Cartesian Therapeutics worth $76.3K as of Q2 2026.
  • Cartesian Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4044 holding.
  • 88 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.